TFF Pharmaceuticals Inc (TFFP)
2.20
+0.04
(+1.85%)
USD |
NASDAQ |
May 17, 16:00
2.20
0.00 (0.00%)
After-Hours: 20:00
TFF Pharmaceuticals Cash from Financing (TTM): 5.013M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.013M |
| September 30, 2023 | 16.35M |
| June 30, 2023 | 11.69M |
| March 31, 2023 | 11.73M |
| December 31, 2022 | 11.75M |
| September 30, 2022 | 0.4147M |
| June 30, 2022 | -0.016M |
| March 31, 2022 | 0.026M |
| December 31, 2021 | 28.88M |
| Date | Value |
|---|---|
| September 30, 2021 | 29.60M |
| June 30, 2021 | 53.88M |
| March 31, 2021 | 53.85M |
| December 31, 2020 | 24.99M |
| September 30, 2020 | 46.13M |
| June 30, 2020 | 21.84M |
| March 31, 2020 | 29.05M |
| December 31, 2019 | 29.05M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.016M
Minimum
Jun 2022
53.88M
Maximum
Jun 2021
22.01M
Average
21.84M
Median
Jun 2020
Cash from Financing (TTM) Benchmarks
| Lifecore Biomedical Inc | 56.06M |
| Jaguar Health Inc | 27.68M |
| Genprex Inc | 10.59M |
| Aquestive Therapeutics Inc | 94.92M |
| NovaBay Pharmaceuticals Inc | 1.313M |